Paul Giresi

Hemi Ventures LLC (Hemi Ventures) is a venture capital firm founded in 2016 by Amy Gu. The firm is headquartered in Palo Alto, California.

Accent Therapeutics, Inc. operates as a biopharmaceutical company which develops treatments for cancer patients. The company was founded by Howard Y. Chang, Chuan He and Robert A. Copeland in September 2017 and is headquartered in Lexington, MA.

Cartography Biosciences, Inc. is a biotech company that specializes in developing tumor-selective therapeutics using a unique genomics and computational platform. The company is based in Foster City, CA. The company integrates data from proprietary sample sourcing relationships, a comprehensive reference atlas, and target identification algorithms to identify the cells of interest and the single or pairs of targets that are most specific to the intended target cells. Cartography Biosciences is unlocking the full potential of immunotherapy by discovering and developing therapeutics as precise as their targets. The company was founded by Ansuman Satpathy, Howard Y. Chang, Kevin Parker. Kevin Parker has been the CEO since incorporation.

Orbital Therapeutics, Inc. is a company based in Cambridge, MA that aims to enhance health by utilizing RNA-based medicines to treat human diseases in innovative ways. The company is building a platform that combines RNA technology delivery methods, data science, and automation to develop a portfolio of medicines focused on vaccines, immunomodulation, protein replacement, and regenerative medicine. The company was founded by Drew Weissman, John M. Maraganore, Kristina M. Burow, Ravindra Majeti, Giuseppe Ciaramella, Eugene W. Yeo, Howard Y. Chang, and Carol Suh, with Giuseppe Ciaramella serving as the CEO since incorporation.

Protillion Biosciences, Inc. is a company based in Burlingame, CA that was founded in 2019 by Will Greenleaf, David R. Walt, and Curtis Layton. The company specializes in commercializing disruptive technology for therapeutic antibody and binder discovery. The company's high throughput instrumentation can characterize the binding affinity on the order of 1 million antibody variants in a 2-day automated run, enabling the identification of better antibody candidates on an exponentially faster timeline compared to current state-of-the-art antibody discovery and optimization techniques that may take months of laborious laboratory procedures executed by highly-skilled practitioners. Curtis Layton has been the CEO since 2019.